A Randomized Phase I/II Study to Assess the Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-Level Deep Venous Thrombosis

Trial Profile

A Randomized Phase I/II Study to Assess the Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-Level Deep Venous Thrombosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs GMI 1271 (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis
  • Focus Adverse reactions
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 24 Apr 2017 Status changed from recruiting to completed.
    • 08 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 22 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top